Scotiabank restated their outperform rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research note released on Thursday morning. The firm currently has a C$5.00 price objective on the stock.
A number of other equities research analysts have also issued reports on PLI. Royal Bank Of Canada reiterated an outperform rating on shares of ProMetic Life Sciences in a research note on Wednesday, June 15th. CIBC lowered their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Finally, TD Securities reiterated a speculative buy rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research note on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of C$4.84.
ProMetic Life Sciences (TSE:PLI) remained flat at $3.09 during midday trading on Thursday. The company had a trading volume of 298,417 shares. The stock has a 50 day moving average of $2.92 and a 200-day moving average of $3.01. ProMetic Life Sciences has a 1-year low of $1.67 and a 1-year high of $3.62. The company’s market capitalization is $1.87 billion.